What is known and Objective: Hypertension, a major risk factor for adverse cardiovascular events, such as stroke and myocardial infarction, affects 80 million American adults. The aetiology of hypertension is multifaceted and difficult to identify. Dopamine receptors, especially those in the kidneys, play a role in blood pressure regulation, and alterations in their function can cause hypertension. The objective of this review was to investigate the association between the use of dopamine antagonists with hypertension focusing especially on second-generation antipsychotics, like clozapine that is D4 receptor antagonist.
in opposition to, hormonal regulators, including aldosterone, norepinephrine, epinephrine, endothelin, prolactin, renin and vasopressin. Dopamine receptors, especially those in the kidneys, play a direct role in BP regulation. Dopamine exerts its effect via a family of cell surface G protein-coupled receptors (GPCRs), classified as D1-like (ie, D1 and D5) and D2-like (ie, D2, D3 and D4). Among these receptors, D1, D3 and D4 receptors interact with the renin-angiotensin-aldosterone system (RAAS), whereas the D2 and D5 receptors interact with the sympathetic nervous system to regulate BP. 4, 5 It has also been shown that stimulation of both D1 and D5 receptors directly inhibits renal tubular Na + reabsorption. 6, 7 Therefore, the clinical use of dopaminergic agonists or antagonists could disturb the regulation of BP leading to either hypo-or hypertension, respectively.
Most antipsychotic agents utilized in the treatment of schizophrenia, bipolar disorder and other psychoses are dopaminergic antagonists of the D2-like family, primarily D2 antagonists, and some are D4
antagonists (eg, clozapine). 8 Older antipsychotic agents (ie, phenothiazine and haloperidol) target D2 receptors, whereas newer antipsychotics (ie, clozapine, olanzapine) target D4 receptors. Fenoldopam is a peripherally acting D1 dopamine receptor agonist used clinically to lower blood pressure in hypertensive emergencies. 9 Non-selective dopaminergic agonists are also used to treat Parkinson's disease and attention deficit hyperactivity disorder (ADHD) for improvement of motor and cognitive activities, respectively. 8 Dopamine receptor affinities for commonly used antipsychotics are described in Table 1 . 10 However, to our knowledge, systematic studies investigating the effect of selective dopamine receptor agonists and antagonists on BP do not exist. The primary objective of this systematic review is to investigate the association between the use of dopaminergic agonists or antagonists and HTN to improve the patient safety outcome and to facilitate clinical decision-making in pharmacotherapy. 
| METHODS

| RESULTS AND DISCUSSION
Based on the prespecified criteria, 11 articles were included in our analysis. Out of these studies, 5 studies were conducted on animal models (rats/mice) and 6 were human trials. Main results and implications of these studies are discussed in Table 2 .
| RAAS and the kidneys
The RAAS is critical for body homeostasis. It works to retain fluids and electrolytes in a variety of ways, many of which involve renal handling of fluids and electrolytes, which are opposed by other systems in the body, in particular, the dopaminergic system. As recently 
| Dopaminergic receptors and blood pressure
As aforementioned, dopamine is produced locally in the kidneys and takes part in the regulation of renal tubular Na+ transport. 4 Of note, dopamine also regulates jejunal Na + transport from the gut. 4 Under conditions of normal Na+ intake, dopamine decreases renal Na+ transport and retention in the body opposite of the RAAS function.
5
A deficient dopaminergic response to increased Na+ intake plays a major role in HTN, which can be explained by a failure to decrease renal or jejunal Na+ transport. 5 If the dopamine receptor is uncoupled from its G protein complex, transduction of the dopaminergic signal to decrease Na+ transport is impaired. 5 As dopamine receptors belong Determine which dopamine receptor subtype would alter sodium and water metabolism thereby affecting BP An association was found between the "long" and "short" dopamine receptor allele (DRD4) and systolic (P = .031) and diastolic BP (P = .034).
Interaction between D4 receptor and BP with increasing age was found
The effects of genes on the level of BP differ over time, either because they are active during a critical period in the evolution of HTN or because they contribute to age-related target organ effects caused by HTN to the GPCR family, they are further divided into 2 subfamilies, the D1-like and D2-like receptors. 4 The D1-like receptors include D1 and D5 receptors, which primarily activate the G s protein to stimulate adenylyl cyclase and its downstream pathways. There is some G protein promiscuity among dopamine receptors. For instance, in the presence of the adaptor protein calcyon, phospholipase C, calcium channels are also stimulated by the D1 family of dopamine receptors. 4 In contrast, D2-like receptors, which include D2, D3 and D4 receptor subtypes, primarily interact with the G i protein to inhibit adenylyl cyclase and open potassium (K+) channels. 4 The impaired transduction of the dopamine signal in some organs in HTN is mainly caused by diminished D1-like receptor function. 4 In this situation, function is impaired in the proximal tubule and ascending limb of Henle, but not in cortical collecting duct or the distal tubule ( Figure 1 ).
D1 and D2 receptors both affect kidney function. D1 receptors inhibit renal tubular basolateral Na+/K+ ATPase and luminal Na+/H antiporter, and decrease tubular Na+ reabsorption. In contrast, activation of D2 receptors stimulates Na+/K+ ATPase. 8 However, when co-expressed, D1 and D2 receptors can work synergistically to decrease tubular Na + reuptake. 12 The D1-like receptors decrease renal tubular Na+ transport, thereby increasing Na+ excretion.
Impaired D1-like receptor functionality in genetic HTN is mediated by decreased production of cyclic AMP and decreased inhibition of transporters leading to increased renal Na+ retention, which can increase BP. 4 In one study examining the role of dopamine receptors in the kidneys, interaction with the RAAS is well defined. 4 With the ad- Another D2-like receptor, the D4 receptor, may also regulate BP.
Mice in which the D4 receptor is knocked out are also hypertensive, and both kidney and brain AT 1 receptors are increased in the D4 receptor knockout mouse. 13 Interestingly, AT 1 receptor activation increases D4 receptor expression in rat kidney proximal tubule cells in culture and increases D4 receptor-mediated natriuresis. 14 In contrast, activation of the D4 receptor downregulates AT 1 receptor expression in the mouse kidney. 13 The mutant mouse with a non-functional D2 receptor mutation also has increased BP due to increased vasoconstrictor effects of sympathetic nervous system activation and endothelin type B receptor activation. 4 A study by Sen and colleagues showed the association between a D4 receptor polymorphism for repeats of a 16-amino acid sequence that interacts with G proteins and BP. 16 D4 receptors, which are located on the juxtaglomerular and cortical collecting duct cells, alter blood pressure by changing Na+ and water balance. An association was found between the "long" (7, 8 or 10 repeats of the 16-amino acid sequence) and "short" (less than 7 of the repeat sequences) dopamine receptor allele on blood pressure. Systolic BP (P = .031) and diastolic BP (P = .034) were significantly elevated with the "long" allele in a Caucasian population. They also found an association between the "long" D4 receptor polymorphism and elevated BP with increasing age.
16
Zhang and colleagues investigated dopamine regulation of renal renin release and the potential role of macula densa COX-2 in dopaminergic regulation of renal renin synthesis and release in vivo. 17 This study showed that dopamine acting at D1 receptors inhibits COX-2 activity, which indirectly inhibits renin secretion by increasing the delivery of Na + to the macula densa.
To study the importance of the D4 receptor on BP regulation, a strains, but the effect was prolonged (> 45 min) in D4 −/− mice. By contrast, bolus injections of Ang II increased MAP in a dose-dependent manner in both strains with higher increases in D4 −/− at all doses. 18 The study showed that the increase in BP due to activation of AT 1 receptor in the brain was greater when the D4 dopamine receptors were non-functional. 18 This suggests that further evaluation of D4 receptor function in the pathogenesis of the human essential HTN is warranted.
| Clozapine and dopamine receptors
The use of antipsychotic medications that block D2 and D4 receptors, such as clozapine, is associated with increased risk of HTN and cardiovascular morbidity. The incidence of hypotension and HTN among clozapine users is 9% and 4%, respectively, regardless of the duration of treatment.
22
Furthermore, it has been demonstrated that patients on clozapine are at an increased risk for 10-year mortality from cardiovascular disease secondary to clozapine-associated medical disorders such as obesity, diabetes, HTN and hyperlipidemia. 22 This risk appears higher in African
Americans and Hispanics compared to Caucasian patients. In addition to causing both hypotension and HTN, clozapine also causes substantial increases in heart rate unrelated to dose. 22 This may indicate that individuals with the normally functioning D4 receptor polymorphism become hypertensive when the D4 receptor is blocked, while individuals with the D4 receptor polymorphism associated with functional impairment do not show this effect of clozapine blockade. Other offtarget effects of clozapine, such as blockade of 5-HT 2 receptors on vascular smooth muscle, may cause hypotensive effects. 22 Henderson and colleagues studied case reports to assess changes in systolic and diastolic BP and treatment of HTN in patients treated with clozapine. 23 Systolic BP and diastolic BP were examined for up to 5 years in 82 patients (91% Caucasian) treated with clozapine with a mean age of 36.4 years. A significant increase in systolic BP (P = .0004) and diastolic BP (P = .0001) occurred with clozapine therapy. 23 Thus, long-term treatment with clozapine in this population has a significant adverse impact on cardiovascular morbidity and mortality.
In a retrospective study, BP changes in Korean schizophrenic inpatients treated with clozapine and olanzapine were investigated over 8 weeks. 24 In this study, patients received clozapine (n = 70) or olanzapine (n = 97). BP was measured before the start of medication and after 8 weeks. For the clozapine group, there was a significant increase in systolic (3.0 mm Hg, P = .031) and diastolic (3.7 mm Hg, P = .001)
BP. Interestingly, no significant changes were found in the olanzapinetreated patients. The authors stated that the increase in BP could not be attributed to weight gain, as the clozapine-treated group had less weight gain than the olanzapine-treated group, and that the weight gain in the clozapine-treated group did not correlate with the increase in BP. 24 A case report assessing the relationship between HTN and hypokalemia in a patient on varying doses of clozapine showed that HTN and hypokalemia increased while up-titrating clozapine. 25 Treatment with metoprolol succinate and K+ supplementation along with decreasing the dose of clozapine resulted in partial correction of HTN and hypokalemia. Of note, the normal ratio of plasma aldosterone to renin concentration ruled out primary aldosteronism and renal artery stenosis as possible causes of the hypokalemic HTN. It was concluded that clozapine likely caused hypokalemia through renal K+ loss in exchange for Na + reabsorption. 25 
| LIMITATIONS
All studies included in this review suggest a causal relationship between dopaminergic drugs and blood pressure. However, this review has some limitations. First, several of the studies included in this review were performed on experimental animals, which limits the direct application to human populations. Second, all studies included in our research have different study designs and were not directed to assessment of the same outcomes. Despite these limitations, a role of the dopaminergic system in human BP regulation should not escape the attention. antagonists.
| CONCLUSION
